Around 90% of the over 37 million Americans with diabetes have Type 2 diabetes, a condition associated with obesity, according to the CDC
To assess the associations of semaglutide with recurrent CUD, the study population included 8196 patients with T2D who had active medical encounters for T2D diagnosis in 12/20175/2021, were for the first time prescribed semaglutide or non-GLP1-1RA anti-diabetes medications during 12/20175/2021(index event), had a diagnosis of CUD on or before the index event, and had a diagnosis of at least one of obesity-associated comorbidities on or before the index event
Benefits Decreased appetite and cravings Weight loss Improved blood glucose control Feel fuller faster Better sleep patterns Risk of serious side effects increases in patients with hypoglycemia (low blood sugar), kidney problems, and risk of allergic reactions.
Most minor itching resolves with increased hydration, moisturizing skin care, and time as your body stabilizes on the medication
For more information, see this post